AzTrials
AzTrials

Colorectal NeoplasiaNCT06333392

Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial

A study testing Total underwater colonoscopy and Conventional colonoscopy in people with Colorectal Neoplasia and Screening Colonoscopy, run by Vestre Viken Hospital Trust at 5 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Read more about this study

Who is it for?
Ages 55 to 60 years
What is being tested?
Total underwater colonoscopy and Conventional colonoscopy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,070 participants
Where
5 sitesin 2 countries
Study dates
23 Oct 2024to Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • All individuals referred to colonoscopy after a positive FIT screening at the participating screening centres

Who cannot join

  • Individuals with a CRC diagnosis within the last 10 years.

Trial locations and contacts

5 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Anna Lisa Schult, MD, PhD contact

+47 67 80 94 00

anschu@vestreviken.no

Thomas de Lange, MD, associate prof contact

thomas.de.lange@gu.se

5 sites in 2 countries

Norway4 sites, 4 recruiting
  • Vestre Viken Health Trust, Bærum Hospital

    Drammen, 3004

    Anna Lisa Schult, MD PhD, 0047413930003, anschu@vestreviken.no

    Stine Hvattum, MD

    Recruiting
  • Østfold Hospital Health Trust

    Grålum, 1714

    Dung H Nguyen, MD, 004769860000, dung.hong.nguyen@so-hf.no

    Recruiting
  • Akershus University Hospital Health Trust

    Lørenskog, 1478

    Jan Henrik Rydning, MD, 0047 67 96 00 00, jan.henrik.rydning@ahus.no

    Stephan Brackmann

    Recruiting
  • Ullevål University Hospital Health Trust

    Oslo, 0424

    Ingrid M Mikalsen, MD, 004722118080, inmika@ous-hf.no

    Marte L Høivik, MD PhD, m.l.hoivik@medisin.uio.no

    Recruiting

Other trials in Norway

Sweden1 site, 1 recruiting
  • Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden, Department of Medicine, Geriatrics and Emergency Care Mölndal

    Gothenburg

    Thomas de Lange, Associate professor, +46702794054, thomas.de.lange@gu.se

    Recruiting

Other trials in Sweden

About this study

Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:

  1. SSLs will be more visible as they "float" on the submucosa and contract into the lumen, while full distension by gas stretches the mucosa, making detection of flat lesions more difficult.
  2. Water works like a magnifying lens, making detection and detailed characterisation of lesions easier.
  3. uEMR is eased.
  4. Improved bowel cleansing
Read more

The goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2) insufflation and TUC during withdrawal in patients participating in colonoscopy in the Norwegian and Swedish colorectal cancer screening programme after a positive fecal immunochemical test.

The overarching research questions of the present trial is whether colonoscopy outcomes are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the new technique reduces the ecological footprint of the colonoscopy examination.

The project has five main hypotheses:

  1. TUC is superior to the standard approach (CO2 withdrawal) regarding detection of proximal SSLs.
  2. TUC increases the rate of complete resection of lesions \>= 10mm.
  3. TUC reduces the rate of painful colonoscopies and vasovagal reactions.
  4. TUC reduces the health care costs by reduced use of single use accessories and reduced number of redundant colonoscopies to obtain polypfree colon.
  5. TUC reduces the carbon footprint by reduced use of single use accessories.

If TUC is superior to gas insufflation, the technique may be implemented rapidly since the technique is easy to learn. This study will increase endoscopy competence at participating centres. The centres are involved in national colonoscopy training programs, so the technique will quickly be passed on to other hospitals and screening centres.

The trial can be linked to three of the Global Goals:

  • Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor).
  • Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening.
  • Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced.
Being tested
Total underwater colonoscopy, Conventional colonoscopy
Keywords
colorectal cancer screening, screening colonoscopy, underwater colonoscopy
Medical subject headings
Colorectal Neoplasms, Syncope, Vasovagal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Total underwater colonoscopyProcedure or surgery

    one grooup will be randomized to receive a total underwater colonoscopy

  • Conventional colonoscopyProcedure or surgery

    one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal

Study groups in NCT06333392
Study groupRoleWhat they receive
Conventional colonoscopy (CO2) groupActive comparatorthis groups receives conventional colonoscopy with CO2 withdrawal
Receives: Procedure: Conventional colonoscopy
Total underwater colonoscopy (TUC) groupExperimentalThis group receives total underwater colonoscopy
Receives: Procedure: Total underwater colonoscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proximal sessile serrated lesion detection rate

    The proportion of colonoscopies where at least one proximal SSL is detected

    Measured: when histopathology report is clear, about 4 weeks after colonoscopy

Secondary outcomes (11)
  1. Complete resection rate for lesions > 10mm

    see above

    Measured: 4 weeks after colonoscopy

  2. Rate of painful procedures and vasovagal reactions

    se above

    Measured: during and immediately after colonoscopy

  3. Leakage after colonoscopy

    water leakage on the way home after colonoscopy

    Measured: Questionnaire 1-7 days after colonoscopy

  4. Detection rate for other neoplasia than SSL

    see above

    Measured: about 4 weeks after colonoscopy

  5. Withdrawal time

    see above

    Measured: immediately after colonoscopy

  6. Total procedure time

    see above

    Measured: immediately after colonoscopy

  7. Bowel cleansing quality

    with help of BBPS

    Measured: immediately after colonoscopy

  8. Complications

    Significant bleedings and perforations

    Measured: within 30 days after colonoscopy

  9. Number of colonoscopies to achieve polyp free colon

    see above

    Measured: after last colonoscopy per patient

  10. Single use accessories for the procedure

    number of single use accesoires per colonoscopy

    Measured: immediately after colonoscopy

  11. Willingness to repeat colonoscopy

    Willingness to repeat colonoscopy the same way if new colonoscopy is necessary

    Measured: questionnaire 1-2 weeks after colonoscopy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2024
  2. Study start23 Oct 2024
  3. Primary completionDec 2026 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,070 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06333392
Sponsor's protocol ID
TotalUnderwater_REK577567
Status last verified
Sep 2026
First submitted
20 Mar 2024
Last updated
4 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Total underwater colonoscopy and Conventional colonoscopy in people with Colorectal Neoplasia and Screening Colonoscopy, run by Vestre Viken Hospital Trust at 5 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Norway, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anna Lisa Schult, MD, PhD (+47 67 80 94 00, anschu@vestreviken.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proximal sessile serrated lesion detection rate (time frame: when histopathology report is clear, about 4 weeks after colonoscopy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in